Clemedi Update Q4 2022

Clemedi Update Q4 2022

Dear investors, partners, supporters and friends,

we closed the year by increasing our marketing efforts. You might have noticed an increased frequency of linkedIn posts, which we kindly ask you to like and repost. Exhibiting at the MEDICA fair brought in a large number of customer leads which we will be following-up and bring to close during 2023.


We are actively raising funds to finance our market entry in Europe and India as well as expanding the scope of our active tuberculosis product to latent tuberculosis. Interested investors please contact our CEO or refer to our investor page.

Business Development

Clemedi was an exhibitor at MEDICA in Düsseldorf (Europe’s largest medical trade fair) with our booth being part of the Swiss pavillon. We want to thank Innosuisse for their support. We were met with a large interest, particularly from companies and individuals from high tuberculosis burden countries such as India, the Phillippines and several Africa countries. We returned from MEDICA with many new business leads to explore in the next quarter.

Company Development

We look forward to expanding our marketing and sales capability through partnering with distributors in certain geographies. We are happy to have secured a white-label agreement with ThermoFisher for EMEA.

Product development

We have extended our Innosuisse grant until the end of February 2023, securing important resources at the Univsersity of Bern for a while longer. We have also generated all missing data to complete the work packages of the project. Currently, we are focussing on writing and submitting manuscripts highlighting the different advantages of our assay.

Press and social media coverage

Clemedi has been features in several outlets this quarter. We are particularly happy to be featured in the November Issues of Biospectrum India (see article below). Our CEO Sebastian Dümcke was interviewed in a publication from the Swiss State Secretariat for Research and Innovation (SERI). You might have also been following along with our press releases regarding in particular our next product for latent tuberulosis which has been circulated by the Max-Planck Society.

To increase our reach on LinkeIn we invite you to follow our company page by clicking ‘Follow’.